Batya Davidovici

Dr. Batya Davidovici

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2010 in Clinics in Dermatology
Verified
Journal Article
Closed access
BDBatya Davidovici
Batya Davidovici
RWRonni Wolf
Ronni Wolf

1 May 2010 in Clinics in Dermatology
Verified
Journal Article
Closed access
BDBatya Davidovici
Batya Davidovici
RWRonni Wolf
Ronni Wolf

13 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MMMaya Engler Markowitz
Maya Engler Markowitz
YNYehonatan Noyman
Yehonatan Noyman
IKIsrael Khanimov
Israel Khanimov
IZItay Zahavi
Itay Zahavi
BDBatya Davidovici
Batya Davidovici
ALAssi Levi
Assi Levi
Background: Solar urticaria is a rare and disabling photodermatosis. Due to its low prevalence, most available data regarding treatment are derived from observational studies and case series, and a systematic evaluation of treatment efficacy is lacking. This systematic review and meta-analysis aims to assess therapeutic outcomes across treatment modalities in order to guide clinical care. Methods: We conducted a systematic literature search across PubMed, ScienceDirect, the Cochrane Library, and ClinicalTrials.gov. Studies reporting treatment outcomes in patients with solar urticaria were included. Pooled response rates were calculated for each treatment modality. Results: Out of 508 studies initially identified, 38 met the inclusion criteria. Antihistamines were evaluated in 21 studies (376 patients), with a pooled response rate (partial or complete) of 83.0% (95% CI, 70.4–91.1%) and a complete response rate of 7.7% (95% CI, 1.7–28.3%). Phototherapy was assessed in 11 studies (145 patients), showing a similar overall response (89.8%; 95% CI, 77.9–95.3%) but a higher complete response rate (39.8%; 95% CI, 18.3–66.1%). Omalizumab, evaluated in nine studies (76 patients), demonstrated the highest efficacy, with 93.2% (95% CI, 73.8–98.5%) achieving response and 68.4% (95% CI, 48.5–83.2%) complete remission. Limited data on IVIG, cyclosporine, and plasmapheresis suggested partial efficacy in selected refractory cases. Conclusions: This meta-analysis may support clinical decision-making by clinicians. A stepwise approach is suggested: high-dose H1 antihistamines as first-line therapy, phototherapy as an alternative option in patients with access to treatment centers, and omalizumab for those with insufficient response. In refractory cases, additional options might be considered.

29 June 2022 in Dermatologic Therapy
Verified
Journal Article
Closed access
MGMirit Gluck
Mirit Gluck
EHEmmilia Hodak
Emmilia Hodak
BDBatya Davidovici
Batya Davidovici
Immunosuppressive agents are essential for graft survival in solid-organ transplant recipients (SOTRs), but they have substantial durable side effects, including a higher incidence of aggressive nonmelanoma skin cancers (NMSCs). Hitherto, only one class of immunosuppressants, mammalian target of rapamycin inhibitors (mTORi), may inhibit skin tumor formation, however their durable effectiveness is controversial. To evaluate the sustained effectiveness of mTORi in reducing NMSCs' incidence in SOTRs, a retrospective study was conducted in a specialized dermatology clinic for SOTRs of a tertiary university-affiliated medical center. SOTRs with a history of at least one histologically proven NMSC were followed for 6 years: 3 years after transplantation, before initiation of mTORi, and 3 years under mTORi treatment. The cohort consisted of 44 SOTRs. Treatment with mTORi was initiated on average 6.27 (3.34-6.34) years following transplantation. In the 3 years before mTORi treatment initiation, the mean number of new NMSCs per patient was 2.11 (1-14). This value decreased to 1.2 (0-19) in the 3 years under mTORi treatment (p = 0.0007). Analysis by NMSC type yielded a significant decrease in both SCCs and BCCs. This study found that mTORi are effective for prolonged secondary prevention of NMSCs in SOTRs.

10 April 2022 in International Journal of Dermatology
Verified
Journal Article
Closed access
IAIris Amitay‐Laish
Iris Amitay‐Laish
ESEfrat Solomon-Cohen
Efrat Solomon-Cohen
HFHana Feuerman
Hana Feuerman
EDElena Didkovsky
Elena Didkovsky
BDBatya Davidovici
Batya Davidovici
RSRina Segal
Rina Segal

1 February 2008 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
BDBatya Davidovici
Batya Davidovici
SHSima Halevy
Sima Halevy